Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 2/20 | 0.53 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.53 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.50 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.47 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.47 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.47 |
| ▸ | MIF | P14174 | 1/20 | 0.46 |
| ▸ | FDFT1 | P37268 | 2/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | DAO | P14920 | 5/20 | 0.42 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3245715 | 0.98 | HDAC1 (0.51) | HDAC1HDAC8TAAR1PTPN2PTPN1 | |
| SCHEMBL3244842 | 0.94 | TAAR1 (0.52) | HDAC1HDAC8TAAR1PTPN2PTPN1 | |
| SCHEMBL2702138 | 0.86 | TAAR1 (0.55) | HDAC1HDAC8TAAR1MIFFDFT1 | |
| SCHEMBL5539490 | 0.86 | PTPN2 (0.45) | HDAC1HDAC8TAAR1PTPN2PTPN1 | |
| SCHEMBL5543449 | 0.84 | PTPN2 (0.44) | HDAC1HDAC8TAAR1PTPN2PTPN1 | |
| SCHEMBL5535935 | 0.80 | PTPN2 (0.42) | HDAC1HDAC8TAAR1PTPN2PTPN1 | |
| SCHEMBL5541662 | 0.80 | DAO (0.41) | HDAC1HDAC8DAOIDO1 | |
| SCHEMBL18243485 | 0.79 | HDAC1 (0.57) | HDAC1HDAC8TAAR1PTPN2PTPN1 | |
| SCHEMBL5538115 | 0.79 | TAAR1 (0.45) | TAAR1MAOB | |
| SCHEMBL5536424 | 0.77 | HDAC1 (0.49) | HDAC1HDAC8TAAR1PTPN2PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| EP-1658846-B1 | N-(8,8,8-trifluorooctyl)-1,5-dideoxy-1,5-imino-D-glucitol for treating hepatitis virus infections | UNITED THERAPEUTICS CORP (US) | 2008-07-30 | — | — | EP | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-20060264468-A1 | Use of substituted-1, 5-dideoxy-1, 5-imino-D-glucitol compounds for treating hepatitis virus infections | UNITED THERAPEUTICS CORPORATION | 2006-11-23 | — | — | US | disclosed |
| EP-1658846-A1 | Substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds for treating hepatitis virus infections | G.D. SEARLE & CO. (US) | 2006-05-24 | — | — | EP | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
| US-6747149-B2 | ADMINISTERING VIRICIDES SUCH AS N-NONENYL GLUCOSAMINE, AND OPTIONALLY WITH MIXTURES OF NUCLEOSIDES, NUCLEOTIDES, IMMUNOMODULATORS OR IMMUNOSTIMULANTS FOR PROPHYLAXIS VIRAL DISEASES | G. D. SEARLE & CO. | 2004-06-08 | — | — | US | disclosed |
| US-20030220299-A1 | Especially treating hepatitis B and hepatitis C; may be used alone, or in combination with another antiviral agent such as nucleosides, nucleotides, immunomodulators, and/or immunostimulants | G.D. SEARLE & CO. | 2003-11-27 | — | — | US | disclosed |
| US-20030195229-A1 | Glucamine salts for treating hepatitis virus infections | PHARMACIA CORPORATION | 2003-10-16 | — | — | US | disclosed |
| US-6545021-B1 | Including ether and ester derivatives as well as N-carbonyl derivatives | G.D. SEARLE & CO. | 2003-04-08 | — | — | US | disclosed |
| US-6515028-B1 | Used alone, or in combination with another antiviral agents selected from among nucleosides, nucleotides, immunomodulators, immunostimulants or various combinations of such other agents | G.D. SEARLE & CO. | 2003-02-04 | — | — | US | disclosed |
| EP-1173161-A2 | GLUCAMINE COMPOUNDS FOR TREATING HEPATITIS VIRUS INFECTIONS | G.D. SEARLE & CO. (US) | 2002-01-23 | — | — | EP | disclosed |
| EP-1165080-A2 | USE OF SUBSTITUTED-1,5-DIDEOXY-1,5-IMINO-D-GLUCITOL COMPOUNDS FOR TREATING HEPATITIS VIRUS INFECTIONS | G.D. SEARLE & CO. (US) | 2002-01-02 | — | — | EP | disclosed |
| WO-2001008672-A2 | GLUCAMINE COMPOUNDS FOR TREATING HEPATITIS VIRUS INFECTIONS | G.D. SEARLE & CO. (US) | 2001-02-08 | — | — | WO | disclosed |
| WO-2000047198-A2 | USE OF SUBSTITUTED-1,5-DIDEOXY-1,5-IMINO-D-GLUCITOL COMPOUNDS FOR TREATING HEPATITIS VIRUS INFECTIONS | G.D. SEARLE & CO. (US) | 2000-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | HDAC1 322/4885HDAC8 993/4885TAAR1 364/4885 |
| US-20030195229-A1 | Glucamine salts for treating hepatitis virus infections | UGGT1, GYS2, MGAT3 | HDAC1 2495/4885HDAC8 3370/4885TAAR1 870/4885 |
| US-20060264468-A1 | Use of substituted-1, 5-dideoxy-1, 5-imino-D-glucitol compounds for treating hepatitis virus infections | IMPDH1, HAVCR2, DERA | HDAC1 1590/4885HDAC8 2528/4885TAAR1 2855/4885 |
| US-20030220299-A1 | Especially treating hepatitis B and hepatitis C; may be used alone, or in combination with another antiviral agent such as nucleosides, nucleotides, immunomodulators, and/or immunostimulants | IMPDH1, HAVCR2, IMPDH2 | HDAC1 2217/4885HDAC8 2231/4885TAAR1 2403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.